RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 New Analysis of CRYSTAL Results Supports Patient Selection According to RAS Mutation Status to Maximize Benefit from CET Therapy
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 22
SP 9
OP 10
DO 10.1177/155989771422004
UL http://mdc.sagepub.com/content/14/22/9.abstract
AB The randomized Phase 3 Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer trial [CRYSTAL; Van Cutsem E et al. N Engl J Med 2009] investigated the efficacy and safety of cetuximab combined with a simplified regimen of leucovorin–5-flourouracil—irinotecan (FOLFIRI) for the initial treatment of metastatic colorectal cancer.